Bangkok Dusit Medical Services Public Company Limited (SET: BDMS), Thailand’s premier healthcare provider, reported a 7% year-over-year decline in net profit for the second quarter of 2026, totaling THB 3,248 million. While the bottom line faced pressure, consolidated operating income rose slightly by 1% to THB 27.51 billion, illustrating a resilient revenue base despite significant regional disruptions.
Key Financial Highlights:
- Net Profit: THB 3,248 million (-7% YoY).
- Operating Income: THB 27,514 million (+1% YoY).
- EBITDA:THB 6,058 million (-1% YoY).
- Earnings Per Share (EPS): THB 0.20 (-7% YoY).
- Occupancy Rate: 55% (down from 61% in 2Q25).
The quarter’s performance was defined by a widening divergence in patient demographics. Revenue from Thai patients grew 2%, supported by steady demand for necessary medical treatments. Conversely, international patient revenue fell 2%, largely due to a sharp 67% plunge in Cambodian revenues and a 24% drop from the Middle East, both impacted by regional conflicts.
However, adjusting for these specific conflict-hit zones reveals an underlying strength: international revenues excluding Cambodia and the Middle East surged 10%, driven by robust demand from Myanmar (+42%) and the U.S. (+23%).
Profitability was squeezed by a 3% rise in operating expenses, which reached THB 23,310 million. This increase was primarily fueled by higher doctor fees, medical supply costs, and rising depreciation from ongoing hospital expansions. The EBITDA margin softened to 22% from 22.6% a year earlier. Notably, the bottom line was slightly bolstered by a non-recurring THB 90 million flood insurance compensation related to operations in Hat Yai.
BDMS maintains a solid balance sheet with a total interest-bearing debt-to-equity ratio of 0.2x. Finance expenses notably decreased by 15% following the redemption of maturing debentures.
Looking ahead, management is pivoting toward long-term value creation through its THB 29 billion “WellEra” project, a massive wellness ecosystem in Bangkok’s Lumpini district expected to complete in 2030. While regional conflicts remain a monitorable risk, the company has noted a recovery in Middle Eastern patient volumes since the start of the quarter.
